Structure Therapeutics is a clinical‑stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2016 (formerly ShouTi Inc.), it develops oral small‑molecule therapeutics targeting GPCR pathways for chronic metabolic and pulmonary diseases. Its lead asset, GSBR‑1290, is an oral GLP‑1 receptor agonist in Phase 2 trials for obesity and related conditions.